Adam Feuerstein and Damian Garde

BioTech

Amylyx ALS drug failure leaves patients, advocates, and researchers reeling — and wondering what’s next

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with

Adam Feuerstein and Damian Garde March 8, 2024

BioTech

FDA approves first Alzheimer’s therapy shown to clearly slow cognitive decline

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated

Adam Feuerstein and Damian Garde July 6, 2023

BioTech

Alkermes shareholders re-elect directors, rebuffing effort by hedge fund Sarissa

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had

Adam Feuerstein and Damian Garde June 29, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Adam Feuerstein and Damian Garde

Amylyx ALS drug failure leaves patients, advocates, and researchers reeling — and wondering what’s next

FDA approves first Alzheimer’s therapy shown to clearly slow cognitive decline

Alkermes shareholders re-elect directors, rebuffing effort by hedge fund Sarissa

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe